La Clinica terapeutica · 1998
[Monitoring of sE-selectin serum levels in three different dermatoses].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
D'Auria L, Bonifati C, Mussi A, Ameglio F
Аннотация
PURPOSE: To determine the behaviour of serum levels of soluble E-selectin (sE-selectin), the soluble isoform of E-selectin, before/during/after therapy in patients with three.
PATIENTS AND METHODS: Using commercially available ELISA kits, serum levels of sE-selectin have been determined in 15 patients with psoriasis, 15 with pemphigus vulgaris and 15 with bullous pemphigoid, and compared with those of 30 healthy subjects.
RESULTS: The results showed increased serum levels of sE-selectin in the three groups of patients as compared with those of 30 healthy subjects (p < 0.01). In addition, serum levels were significantly correlated with the disease activity expressed as Psoriasis Area and Severity Index (PASI score) (R = 0.56, p = 0.014) in psoriasis, and as number of the visible lesions (blisters/erosions), in the two bullous dermatoses (R = 0.81, p < 0.01). After therapy, the marker levels were significantly decreased (p < 0.01).
CONCLUSIONS: Overall, these data suggest that serum determinations of sE-selectin could represent a clinically useful indicator to monitor therapy.
PATIENTS AND METHODS: Using commercially available ELISA kits, serum levels of sE-selectin have been determined in 15 patients with psoriasis, 15 with pemphigus vulgaris and 15 with bullous pemphigoid, and compared with those of 30 healthy subjects.
RESULTS: The results showed increased serum levels of sE-selectin in the three groups of patients as compared with those of 30 healthy subjects (p < 0.01). In addition, serum levels were significantly correlated with the disease activity expressed as Psoriasis Area and Severity Index (PASI score) (R = 0.56, p = 0.014) in psoriasis, and as number of the visible lesions (blisters/erosions), in the two bullous dermatoses (R = 0.81, p < 0.01). After therapy, the marker levels were significantly decreased (p < 0.01).
CONCLUSIONS: Overall, these data suggest that serum determinations of sE-selectin could represent a clinically useful indicator to monitor therapy.